20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
Repurposing bumetanide for Alzheimer’s
Bumetanide (Bumex) is a diuretic drug (a medication that removes water, by increasing the production of urine). It is used to treat swelling caused by heart failure or liver or kidney disease. It is a widely used drug that has been well characterised in clinical use. Recently researchers conducted a screening […]
Patron Mike Tindall speaks to four families affected by Parkinson’s on BBC Breakfast with Sally Nugent
In a poignant piece for BBC Breakfast, Cure Parkinson’s patron Mike Tindall and BBC presenter Sally Nugent met with Alison Anderson, Amarpal Harrar, Omotola Thomas and David Murray, all of whom are living with Parkinson’s.
‘Sport Parkinson’s Four Nations Golf Tournament’ tees off at The Belfry
From 11-13 October, four teams of golfers who have Parkinson’s, from the four UK nations, will tee off on The Belfry’s Brabazon course for two days of friendly competition and fundraising. Cure Parkinson’s patron, Mike Tindall, will lead the England team.
Making a (G)case for quetiapine
Drug repurposing (repositioning, reprofiling or re-tasking) is a strategy of identifying novel uses for clinically approved (or experimental) drugs that fall outside the scope of the original medical indication. Many drug repurposing efforts have started with screening experiments, looking for drugs with certain properties. Recently, researchers conducted a drug repurposing screening […]
2021 Tom Isaacs Award honours leading Parkinson’s expert: Dr Camille Carroll
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Camille Carroll, Associate Professor in Neurology at University of Plymouth, as this year’s deserving winner of the ‘Tom Isaacs Award’. The award was presented during the parallel, annual Grand Challenges in Parkinson’s Disease…